Posted on 11 September, 2012

Novartis is challenging the part of India’s patent law that says that a new form of an existing medicine can only be patented if it shows significantly improved therapeutic efficacy. This would stop the process of “evergreening” that lets pharma...

Novartis is challenging the part of India’s patent law that says that a new form of an existing medicine can only be patented if it shows significantly improved therapeutic efficacy. This would stop the process of “evergreening” that lets pharma companies keep their patent longer than the original 20-years intended.

This graphic shows how evergreening poses a real threat to accessing life-saving medicines.

Take action: http://www.msfaccess.org/STOPnovartis

Novartis: the world is watching you, and we are not standing by silently. #STOPnovartis

Take action: http://www.msfaccess.org/STOPnovartis